Back to discover
Disease

Hot Flashes

Late-stage therapeutic developmentEmerging research
MeSHHot Flashes
1
Publications
20
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Management of perimenopausal and menopausal symptoms.

Research2023-08-08BMJ (Clinical research ed.)

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones7View
Results posted 1
Results expected 4
Recently completed 2
Activity timeline7

Clinical trials

14 sponsors · 2 new · 1 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
12
Late-stage
6
Completed
Late-stage studies

A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy

Phase 3 · Active, not recruiting · Astellas Pharma Global Development, Inc.

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Phase 2/3 · Recruiting · University of Colorado, Denver

A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for an Additional up to 3.5 Years in Women With Hormone-receptor Positive Breast Cancer:

Phase 3 · Active, not recruiting · Bayer

A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Phase 3 · Completed · Astellas Pharma Inc

A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes

Phase 3 · Completed · Academic and Community Cancer Research United

A Single-Arm Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women in China Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Phase 3 · Completed · Astellas Pharma China, Inc.
Recently completed

A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Phase 3 · Completed · Astellas Pharma Inc

A Single-Arm Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women in China Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Phase 3 · Completed · Astellas Pharma China, Inc.

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Phase 3 · Completed · Astellas Pharma China, Inc.

A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes

Phase 3 · Completed · Academic and Community Cancer Research United

Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance

Phase 4 · Completed · Massachusetts General Hospital

A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes

Phase 3 · Completed · Alliance for Clinical Trials in Oncology

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Management of perimenopausal and menopausal symptoms.

BMJ (Clinical research ed.) · 2023 · 62 cites
Recent publications

Management of perimenopausal and menopausal symptoms.

BMJ (Clinical research ed.) · 2023 · 62 cites
Major themes2
  • Perimenopause1
  • Quality of Life1
Leading journals1
  • BMJ (Clinical research ed.)1
Leading researchers3
  • Duralde ER1
  • Manson JE1
  • Sobel TH1
Affiliations (unnormalised)3
  • Brigham and Women's Hospital1
  • Harvard Medical School1
  • Mayo Clinic Arizona1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A sudden, temporary sensation of heat predominantly experienced by some women during MENOPAUSE. (Random House Unabridged Dictionary, 2d ed)

Identifiers
MeSHHot Flashes
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.